To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 262 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 171 Noes - 265
Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 251 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 39 Noes - 257
Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 261 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 171 Noes - 265
Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Craig Tracey (Con) voted Aye - in line with the party majority and in line with the House
One of 252 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 257 Noes - 38
Speech in Commons Chamber - Thu 21 Mar 2024
Business of the House

Speech Link

View all Craig Tracey (Con - North Warwickshire) contributions to the debate on: Business of the House

Written Question
Trastuzumab Deruxtecan
Thursday 21st March 2024

Asked by: Craig Tracey (Conservative - North Warwickshire)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the decision by the National Institute for Health and Care Excellence to not recommend trastuzumab deruxtecan for HER2-low secondary breast cancer for use on NHS on the life expectancy of eligible women.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of trastuzumab deruxtecan (Enhertu) for the treatment of metastatic HER2-low breast cancer. The NICE published final draft guidance on 5 March 2024, that does not recommend it as a clinically and cost-effective use of National Health Service resources. Stakeholders had until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.


Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 293 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 218 Noes - 305
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 293 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 217 Noes - 305
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 296 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 219 Noes - 306
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Craig Tracey (Con) voted No - in line with the party majority and in line with the House
One of 298 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 224 Noes - 301